Open Access
Sotorasib: First Approval
Тип публикации: Journal Article
Дата публикации: 2021-08-06
SCImago Q1
Tоп 10% SCImago
WOS Q1
БС1
SJR: 3.5
CiteScore: 25.3
Impact factor: 14.7
ISSN: 00126667, 11791950
PubMed ID:
34357500
Pharmacology (medical)
Краткое описание
Sotorasib (LUMAKRAS™) is a RAS GTPase family inhibitor being developed by Amgen for the treatment of solid tumours with KRAS mutations, including non-small cell lung cancer (NSCLC) and colorectal cancer. In May 2021, sotorasib was granted accelerated approval by the US FDA for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy. This article summarizes the milestones in the development of sotorasib leading to this first approval for KRAS G12C-mutated NSCLC.
Найдено
Ничего не найдено, попробуйте изменить настройки фильтра.
Для доступа к списку цитирований публикации необходимо авторизоваться.
Топ-30
Журналы
|
1
2
3
4
5
6
7
8
|
|
|
Cancers
8 публикаций, 3.94%
|
|
|
European Journal of Medicinal Chemistry
8 публикаций, 3.94%
|
|
|
bioRxiv
8 публикаций, 3.94%
|
|
|
Journal of Medicinal Chemistry
7 публикаций, 3.45%
|
|
|
International Journal of Molecular Sciences
6 публикаций, 2.96%
|
|
|
Frontiers in Oncology
5 публикаций, 2.46%
|
|
|
Signal Transduction and Targeted Therapy
5 публикаций, 2.46%
|
|
|
Future Oncology
3 публикации, 1.48%
|
|
|
Molecules
3 публикации, 1.48%
|
|
|
Pharmaceuticals
3 публикации, 1.48%
|
|
|
Molecular Biomedicine
3 публикации, 1.48%
|
|
|
Biomedicine and Pharmacotherapy
3 публикации, 1.48%
|
|
|
Bioorganic Chemistry
3 публикации, 1.48%
|
|
|
ChemBioChem
3 публикации, 1.48%
|
|
|
Bioanalysis
2 публикации, 0.99%
|
|
|
Biomedicines
2 публикации, 0.99%
|
|
|
Frontiers in Pharmacology
2 публикации, 0.99%
|
|
|
Frontiers in Molecular Biosciences
2 публикации, 0.99%
|
|
|
Oncogene
2 публикации, 0.99%
|
|
|
Medical Oncology
2 публикации, 0.99%
|
|
|
Biochemical Pharmacology
2 публикации, 0.99%
|
|
|
Cells
2 публикации, 0.99%
|
|
|
Organic Letters
2 публикации, 0.99%
|
|
|
Therapeutic Advances in Medical Oncology
2 публикации, 0.99%
|
|
|
Journal of the American Chemical Society
2 публикации, 0.99%
|
|
|
RSC Medicinal Chemistry
2 публикации, 0.99%
|
|
|
Results in Chemistry
2 публикации, 0.99%
|
|
|
Molecular Cancer Therapeutics
2 публикации, 0.99%
|
|
|
Scientific Reports
2 публикации, 0.99%
|
|
|
1
2
3
4
5
6
7
8
|
Издатели
|
5
10
15
20
25
30
35
40
45
50
|
|
|
Elsevier
46 публикаций, 22.66%
|
|
|
MDPI
29 публикаций, 14.29%
|
|
|
Springer Nature
28 публикаций, 13.79%
|
|
|
Wiley
21 публикация, 10.34%
|
|
|
American Chemical Society (ACS)
16 публикаций, 7.88%
|
|
|
Frontiers Media S.A.
10 публикаций, 4.93%
|
|
|
Taylor & Francis
9 публикаций, 4.43%
|
|
|
openRxiv
8 публикаций, 3.94%
|
|
|
Bentham Science Publishers Ltd.
5 публикаций, 2.46%
|
|
|
SAGE
4 публикации, 1.97%
|
|
|
Royal Society of Chemistry (RSC)
3 публикации, 1.48%
|
|
|
American Association for Cancer Research (AACR)
3 публикации, 1.48%
|
|
|
Hans Publishers
2 публикации, 0.99%
|
|
|
Annual Reviews
2 публикации, 0.99%
|
|
|
American Society for Pharmacology and Experimental Therapeutics
1 публикация, 0.49%
|
|
|
Beilstein-Institut
1 публикация, 0.49%
|
|
|
Neoplasia Press
1 публикация, 0.49%
|
|
|
Public Library of Science (PLoS)
1 публикация, 0.49%
|
|
|
Cambridge University Press
1 публикация, 0.49%
|
|
|
Hindawi Limited
1 публикация, 0.49%
|
|
|
American Society of Clinical Oncology (ASCO)
1 публикация, 0.49%
|
|
|
BMJ
1 публикация, 0.49%
|
|
|
Pleiades Publishing
1 публикация, 0.49%
|
|
|
Research Square Platform LLC
1 публикация, 0.49%
|
|
|
OAE Publishing Inc.
1 публикация, 0.49%
|
|
|
S. Karger AG
1 публикация, 0.49%
|
|
|
American Association for the Advancement of Science (AAAS)
1 публикация, 0.49%
|
|
|
The Society of Japanese Women Scientists
1 публикация, 0.49%
|
|
|
American Society for Clinical Investigation
1 публикация, 0.49%
|
|
|
5
10
15
20
25
30
35
40
45
50
|
- Мы не учитываем публикации, у которых нет DOI.
- Статистика публикаций обновляется еженедельно.
Вы ученый?
Создайте профиль, чтобы получать персональные рекомендации коллег, конференций и новых статей.
Войти с ORCID
Метрики
203
Всего цитирований:
203
Цитирований c 2025:
66
(32.52%)
Цитировать
ГОСТ |
RIS |
BibTex |
MLA
Цитировать
ГОСТ
Скопировать
Blair H. A. Sotorasib: First Approval // Drugs. 2021. Vol. 81. No. 13. pp. 1573-1579.
ГОСТ со всеми авторами (до 50)
Скопировать
Blair H. A. Sotorasib: First Approval // Drugs. 2021. Vol. 81. No. 13. pp. 1573-1579.
Цитировать
RIS
Скопировать
TY - JOUR
DO - 10.1007/s40265-021-01574-2
UR - https://doi.org/10.1007/s40265-021-01574-2
TI - Sotorasib: First Approval
T2 - Drugs
AU - Blair, Hannah A.
PY - 2021
DA - 2021/08/06
PB - Springer Nature
SP - 1573-1579
IS - 13
VL - 81
PMID - 34357500
SN - 0012-6667
SN - 1179-1950
ER -
Цитировать
BibTex (до 50 авторов)
Скопировать
@article{2021_Blair,
author = {Hannah A. Blair},
title = {Sotorasib: First Approval},
journal = {Drugs},
year = {2021},
volume = {81},
publisher = {Springer Nature},
month = {aug},
url = {https://doi.org/10.1007/s40265-021-01574-2},
number = {13},
pages = {1573--1579},
doi = {10.1007/s40265-021-01574-2}
}
Цитировать
MLA
Скопировать
Blair, Hannah A.. “Sotorasib: First Approval.” Drugs, vol. 81, no. 13, Aug. 2021, pp. 1573-1579. https://doi.org/10.1007/s40265-021-01574-2.
Ошибка в публикации?